Ellipticine is an antineoplastic agent, whose mode of action is based mainly on DNA intercalation, inhibition of topoisomerase II and formation of covalent DNA adducts mediated by cytochromes P450 and peroxidases. Here, the cytotoxicity of ellipticine to human neuroblastoma derived cell lines IMR-32 and UKF-NB-4 was investigated. Treatment of neuroblastoma cells with ellipticine was compared with that of these cancer cells with doxorubicin. The toxicity of ellipticine was essentially the same as that of doxorubicin to UKF-NB-4 cells, but doxorubicin is much more effective to inhibit the growth of the IMR-32 cell line than ellipticine. Hypoxic conditions used for the cell cultivation resulted in a decrease in ellipticine and/or doxorubicin toxicity to IMR-32 and UKF-NB-4 neuroblastoma cells.

Department of Biochemistry Faculty of Science Charles University Prague Albertov 2030 128 40 Prague 2 CZECH REPUBLIC

Zobrazit více v PubMed

Auclair C. Multimodal action of antitumor agents on DNA: The ellipticine series. Arch Biochem Biophys. 1987;259:1–14. PubMed

Bedrníček J, Vícha A, Jarošová M, Holzerová M, Činátl J, Jr, Michaelis M, Činátl J, Eckschlager T. Characterization of drug-resistant neuroblastoma cell lines by comparative genomic hybridization. Neoplasma. 2005;52:415–419. PubMed

Borek-Dohalská L, Frei E, Stiborová M. DNA adduct formation by the anticancer drug ellipticine and its hydroxy derivatives in human breast adenocarcinoma MCF-7 cells. Collect Czech Chem Commun. 2004;69:603–615.

Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer. 2003;3:203–216. PubMed

Frei E, Bieler CA, Arlt VM, Wiessler M, Stiborová M. Covalent binding of the anticancer drug ellipticine to DNA in V79 cells transfected with human cytochrome P450 enzymes. Biochem Pharmacol. 2002;64:289–295. PubMed

Hardesty CT, Chaney NA, Mead JA. The effect of route of administration on the distribution of ellipticine in mice. Cancer Res. 1972;32:1884–1889. PubMed

Kotchetkov R, Cinatl J, Blaheta R, Vogel JU, Karaskova J, Squire J, Hernáiz Driever P, Klingebiel T, Cinatl J., Jr Development of resistance to vincristine and doxorubicin in neuroblastoma alters malignant properties and induces additional karyotype changes: a preclinical model. Int J Cancer . 2003;104:36–43. PubMed

Lesca P, Beaune P, Monsarrat B. Ellipticines and human liver microsomes: spectral interaction with cytochrome P-450 and hydroxylation. Inhibition of arylhydrocarbon metabolism and mutagenicity. Chem-Biol Interact. 1981;36:299–309. PubMed

Maris JM, Mathay KK. Molecular biology of neuroblastomas. J Clin Oncol. 1999;17:2264–2279. PubMed

Murray GI, Weaver RJ, Paterson PJ, Ewen SW, Melvin WT, Burke MD. Expression of xenobiotic metabolizing enzymes in breast cancer. J Pathol. 1993;169:347–353. PubMed

Stiborová M, Bieler CA, Wiessler M, Frei E. The anticancer agent ellipticine on activation by cytochrome P450 forms covalent DNA adducts. Biochem Pharmacol. 2001;62:1675–1684. PubMed

Stiborová M, Stiborová-Rupertová M, Bořek-Dohalská L, Wiessler M, Frei E. Rat microsomes activating the anticancer drug ellipticine to species covalently binding to deoxyguanosine in DNA are a suitable model mimicking ellipticine bioactivation in humans. Chem Res Toxicol. 2003a;16:38–47. PubMed

Stiborová M, Breuer A, Aimová D, Stiborová-Rupertová M, Wiessler M, Frei E. DNA adduct formation by the anticancer drug ellipticine in rats determined by 32P-postlabeling. Int J Cancer. 2003b;107:885–890. PubMed

DNA and histone deacetylases as targets for neuroblastoma treatment